Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 239 participants.

Also called NCT02288273

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 239 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02288273
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02288273. Randomized; triple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2017-01-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
Intervention (Drug)
Bydureon
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02288273
Content hash
5881214099a15f47eff026b16374a778e67c444056c9a79a06acc5e2fd39d33a